skip to main content, skip to Quick links, or skip to Search

main content

Current Studies:

Photo showing Great Dane

Oncology - Clinical Studies

 

Study Update: Enrollment is complete August 2013

The Impact of Multi-kinase Inhibitor Palladia™ on Angiogenesis and Survival following Amputation and Carboplatin Chemotherapy in Canine Osteosarcoma

* This study supported by a grant from Bone Cancer Dogs

 

Description: Osteosarcoma is the most common bone cancer in dogs. Tumors are locally invasive and have a high rate of metastasis (spread to other places in the body). We are evaluating the use of a novel approach to the treatment of osteosarcoma involving the use of an oral medication (Palladia™) following standard of care treatment (amputation and four cycles of carboplatin chemotherapy). Palladia™ has the ability to disrupt the blood supply to tumor cells and may therefore help delay or prevent the onset of metastasis.

Who to contact: If you have any questions about this study please contact study coordinator, Ms. Julie Nettifee Osborne, RVT, at (919) 513-6812 or via email at julie_osborne@ncsu.edu.

Impact of Palladia™ on Canine Osteosarcoma: Enrollment Complete August 2013

 

Description: Osteosarcoma is the most common bone cancer in dogs. Tumors are locally invasive and have a high rate of metastasis (spread to other places in the body). We are evaluating the use of a novel approach to the treatment of ostesarcoma involving the use of an oral medication (Palladia™) following amputation. Palladia™ has the ability to disrupt the blood supply to tumor cells and may therefore help delay or prevent the onset of metastasis.

Who to contact: If you have any questions about this study please contact study coordinator, Ms. Julie Nettifee Osborne, RVT, at (919) 513-6812 or via email at julie_osborne@ncsu.edu.